Oncology R&D faces the challenge of balancing innovation with efficiency. This analysis delves into how various clinical development decisions influence time to market and the probability of approval, offering strategies to optimize clinical trial design and improve the development process.
- Examine the declining success rates of oncology clinical trials and identify potential causes.
- Explore the strategic decisions that can accelerate access to new medicines, such as pursuing accelerated approval and using surrogate endpoints.
- Compare the impact of innovative program designs, including aggregating and skipping trial phases, on development timelines.
- Provide a framework for making informed decisions that balance speed and risk in oncology drug development.